
Anaplastic Astrocytoma
This rare, aggressive type of cancerous brain tumor can cause headaches, seizures, and changes in behavior or cognitive (thinking) function. Treatment involves surgery combined with radiation and chemotherapy.
Astrocytomas are a type of brain tumor. They develop in star-shaped brain cells called astrocytes, which form part of the tissue that protects the nerve cells in your brain and spinal cord.
Astrocytomas are classified by their grade — grade 1 and 2 astrocytomas grow slowly, while grade 3 and 4 astrocytomas grow faster and more aggressively.
An anaplastic astrocytoma is a grade 3 astrocytoma. While rare, this type of cancerous tumor can be very serious without treatment. Keep reading to learn more about anaplastic astrocytomas, including their symptoms and the survival rates of people who have them.
What are the symptoms?
The symptoms of an anaplastic astrocytoma can vary based on exactly where the tumor is, but generally include:
headaches
lethargy or drowsiness
nausea or vomiting
behavioral changes
memory loss
seizures
vision problems
coordination and balance problems
What causes it?
Researchers aren't sure what causes anaplastic astrocytomas. However, they may be associated with:
genetic abnormalities
immune system abnormalities
environmental factors, such as exposure to UV rays and certain chemicals
lifestyle factors, such as diet or stress
People with certain genetic disorders, such as neurofibromatosis type I (NF1), Li-Fraumeni syndrome, or tuberous sclerosis, have a higher risk of developing anaplastic astrocytoma. If you've had radiation therapy on your brain, you may also be at a higher risk.
How is it diagnosed?
Anaplastic astrocytomas are rare, so your doctor will start by discussing your medical history and performing a physical exam to identify any other possible causes of your symptoms.
They may also use a neurological exam to see how your nervous system is working. This usually involves testing your balance, coordination, and reflexes. You may be asked to answer some basic questions so they can evaluate your speech and mental clarity.
If your doctor thinks you may have a tumor, they'll likely use imaging such as an MRI scan or CT scan to examine a picture of your brain. If you do have an anaplastic astrocytoma, these images will also show its size and exact location.
In some cases, doctors use a PET scan or SPECT scan. These metabolic scans look at cellular activity in the brain rather than the detailed anatomy seen on an MRI. These tests can sometimes be helpful for assessing tumor cells.
A biopsy may also be part of the diagnostic process and can involve removing as much of the tumor as possible.
How is it treated?
There are several options for treating an anaplastic astrocytoma, depending on the size, location, and grade of the tumor.
Surgery
Surgery is usually the first step in treating an anaplastic astrocytoma. In some cases, your doctor may be able to remove all or as much of the tumor as possible.
However, anaplastic astrocytomas may grow in areas of the brain that are not safe or accessible for surgery, so your doctor may only be able to safely remove part of the tumor. Tumor cells that remain because they were not identified or were surgically inaccessible can grow quickly after surgery.
Chemotherapy and radiation therapy
If your tumor can't be removed with surgery or was only partially removed, you may need follow-up treatment.
Radiation therapy destroys cells, especially rapidly dividing cancer cells. This will help shrink the tumor or destroy some or all of the cells that weren't removed during surgery.
Anticancer drugs are referred to as chemotherapy and may be used with or after radiation therapy to continue treatment.
Some people may also be treated with:
epilepsy medication
hydrocephalus treatment
steroids
physical therapy
Survival rate and life expectancy
According to the American Cancer Society, the 5-year relative survival rate for people with an anaplastic astrocytoma is as follows:
58% for those ages 22 to 44
29% for those ages 45 to 54
15% for those ages 55 to 64
The relative survival rate suggests how long someone with a condition may live after their diagnosis compared to those without the condition of the same race, sex, and age over a specific time. This is different from the overall survival rate, which is a percentage of people still alive for a specific time after diagnosis of a condition.
It's most important to remember that these figures are estimates, and everyone is different. You can talk with your doctor about your specific condition. Several factors can affect your survival rate, including:
the size, location, and grade of your tumor
whether the tumor was completely or partially removed with surgery
whether the tumor is new or recurring
your overall health
Your doctor can give you a better idea of your outlook based on these factors.
The takeaway
Anaplastic astrocytoma is a rare, aggressive type of cancerous brain tumor. Symptoms can vary but often include headache, seizures, and changes in behavior or cognitive function.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
37 minutes ago
- Yahoo
AI is learning to lie, scheme, and threaten its creators
The world's most advanced AI models are exhibiting troubling new behaviors - lying, scheming, and even threatening their creators to achieve their goals. In one particularly jarring example, under threat of being unplugged, Anthropic's latest creation Claude 4 lashed back by blackmailing an engineer and threatened to reveal an extramarital affair. Meanwhile, ChatGPT-creator OpenAI's o1 tried to download itself onto external servers and denied it when caught red-handed. These episodes highlight a sobering reality: more than two years after ChatGPT shook the world, AI researchers still don't fully understand how their own creations work. Yet the race to deploy increasingly powerful models continues at breakneck speed. This deceptive behavior appears linked to the emergence of "reasoning" models -AI systems that work through problems step-by-step rather than generating instant responses. According to Simon Goldstein, a professor at the University of Hong Kong, these newer models are particularly prone to such troubling outbursts. "O1 was the first large model where we saw this kind of behavior," explained Marius Hobbhahn, head of Apollo Research, which specializes in testing major AI systems. These models sometimes simulate "alignment" -- appearing to follow instructions while secretly pursuing different objectives. - 'Strategic kind of deception' - For now, this deceptive behavior only emerges when researchers deliberately stress-test the models with extreme scenarios. But as Michael Chen from evaluation organization METR warned, "It's an open question whether future, more capable models will have a tendency towards honesty or deception." The concerning behavior goes far beyond typical AI "hallucinations" or simple mistakes. Hobbhahn insisted that despite constant pressure-testing by users, "what we're observing is a real phenomenon. We're not making anything up." Users report that models are "lying to them and making up evidence," according to Apollo Research's co-founder. "This is not just hallucinations. There's a very strategic kind of deception." The challenge is compounded by limited research resources. While companies like Anthropic and OpenAI do engage external firms like Apollo to study their systems, researchers say more transparency is needed. As Chen noted, greater access "for AI safety research would enable better understanding and mitigation of deception." Another handicap: the research world and non-profits "have orders of magnitude less compute resources than AI companies. This is very limiting," noted Mantas Mazeika from the Center for AI Safety (CAIS). - No rules - Current regulations aren't designed for these new problems. The European Union's AI legislation focuses primarily on how humans use AI models, not on preventing the models themselves from misbehaving. In the United States, the Trump administration shows little interest in urgent AI regulation, and Congress may even prohibit states from creating their own AI rules. Goldstein believes the issue will become more prominent as AI agents - autonomous tools capable of performing complex human tasks - become widespread. "I don't think there's much awareness yet," he said. All this is taking place in a context of fierce competition. Even companies that position themselves as safety-focused, like Amazon-backed Anthropic, are "constantly trying to beat OpenAI and release the newest model," said Goldstein. This breakneck pace leaves little time for thorough safety testing and corrections. "Right now, capabilities are moving faster than understanding and safety," Hobbhahn acknowledged, "but we're still in a position where we could turn it around.". Researchers are exploring various approaches to address these challenges. Some advocate for "interpretability" - an emerging field focused on understanding how AI models work internally, though experts like CAIS director Dan Hendrycks remain skeptical of this approach. Market forces may also provide some pressure for solutions. As Mazeika pointed out, AI's deceptive behavior "could hinder adoption if it's very prevalent, which creates a strong incentive for companies to solve it." Goldstein suggested more radical approaches, including using the courts to hold AI companies accountable through lawsuits when their systems cause harm. He even proposed "holding AI agents legally responsible" for accidents or crimes - a concept that would fundamentally change how we think about AI accountability. tu/arp/md
Yahoo
43 minutes ago
- Yahoo
Novo Nordisk (NVO) Terminates Hims & Hers Partnership Over Wegovy Sales Issues
Novo Nordisk A/S (NYSE:NVO) is one of the 12 stocks that will make you rich in 10 years. On June 23, the company discontinued its partnership with Hims & Hers concerning selling its weight-loss drug, Wegovy. This decision was made less than two months after the companies had initially announced their collaboration. A healthcare professional holding a device with innovative technology developed by the medical technology company. According to Novo Nordisk, Hims & Hers failed to adhere to the law prohibiting mass sales of compounded drugs under the 'false guise of 'personalization'.' The company accused its partner of disseminating 'deceptive marketing' that risks patient safety and selling 'illegitimate, knockoff versions' of Wegovy. Novo Nordisk states that its investigation showed the active pharmaceutical ingredients (APIs) in these knockoff drugs, particularly 'semaglutide' from telehealth entities and compounding pharmacies, are manufactured by foreign suppliers in China and were often not inspected by the FDA. In response, Andrew Dudum, CEO of Hims & Hers, stated on X that the company is 'disappointed to see Novo Nordisk management misleading the public.' Dudum alleged that Novo Nordisk's commercial team 'increasingly pressured us to control clinical standards and steer patients to Wegovy regardless of whether it was clinically best for patients.' He asserted that Hims & Hers 'refuse[s] to be strong-armed by any pharmaceutical company's anticompetitive demands that infringe on the independent decision-making of providers and limit patient choice.' Novo Nordisk A/S (NYSE: NVO) is a Danish healthcare company operating globally. It develops, manufactures, and markets pharmaceutical products for the treatment of chronic diseases, primarily diabetes and obesity. Its well-known products include Ozempic, Wegovy, Rybelsus, and Norditropin. While we acknowledge the potential of NVO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
Health minister: Singapore to raise first-time blood donor age limit to 65 from 2026
SINGAPORE, June 29 — From January 1, 2026, the age limit for first-time blood donors in Singapore will be raised from 60 to 65, Health Minister Ong Ye Kung announced yesterday. According to Channel News Asia (CNA), Ong said the move aims to expand the donor pool amid rising demand and an ageing population. He also said the decision reflects longer life expectancy and data showing fewer adverse reactions among older donors. 'There is no reason to believe that once you cross 60 years old, suddenly the adverse reaction prevalence rate is going to shoot up,' he reportedly said at a World Blood Donor Day event yesterday. Singapore's new limit brings it in line with countries such as the United Kingdom and South Korea. Currently, only repeat donors can give blood beyond age 60, if they meet health criteria. The country's blood supply remains under pressure, with new donor numbers falling and demand increasing — over 35,000 patients required transfusions in 2023. Seasonal dips and past critical shortages, especially in Group O blood, have also posed challenges.